CEBPZ and acute myeloid leukemia: In an analysis of patients with inv(16)/t(16;16) or t(8;21)(q22;q22) CBF AML, 46.2% of patients had c-kit mutations; a lower OS was observed in t(8;21) AML patients with the c-kit TKD(816) mutation but not with c-kit mutations other than TKD(816) [175].